Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three pr…
An institutional-grade, numbers-driven thesis on BSX — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Boston Scientific Corporation (BSX) 68/100 with a 12-month base-case forecast of $66.50 — +34.9% versus the current price of $49.31. Boston Scientific Corporation trades at $49.31 in the Healthcare sector, with a market capitalisation of $73.29B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for BSX is $66.50, implying +34.9% versus the current price. The model's 12-month scenario range runs from $36.68 (bear) to $47.51 (bull), with a base case of $39.65.
On the fundamentals, Boston Scientific shows a P/E of 19.9, trailing revenue of $20.07B, revenue growth of +19.9% YoY. This page also tracks BSX's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
BSX currently carries a TradersQuant composite score of 68/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $66.50 implies +34.9% from $49.31. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for BSX is $66.50, about +34.9% versus the latest price of $49.31. Consensus is based on 44 analysts.
TradersQuant's 12-month model forecast for BSX is a base case of $39.65, ranging from $36.68 (bear) to $47.51 (bull), an expected return of -19.6%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for BSX over the next 12 months is $39.65 in the base case (bear $36.68, bull $47.51), versus today's price of $49.31. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for BSX — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates BSX's fair value at $66.50, implying +34.9% of expected upside versus the current price.
Boston Scientific does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
